Community acquired multi-drug resistant clinical isolates of Escherichia coli in a tertiary care center of Nepal

Antimicrobial Resistance and Infection Control

Shamshul Ansari²  Hari Prasad Nepal²  Rajendra Gautam²  Sony Shrestha²  Puja Neopane²  Ganga Gurung¹  Moti Lal Chapagain² 

[1] College of Nursing, Chitwan Medical College Teaching Hospital, Bharatpur, Chitwan, Nepal

[2] Department of Microbiology, Chitwan Medical College Teaching Hospital, Bharatpur, Chitwan, Nepal

关键词: XDR;    MDR;    MBL;    Escherichia coli;    ESBL;    AmpC;   

Others  :  1183511
DOI  :  10.1186/s13756-015-0059-2

 received in 2014-06-07, accepted in 2015-04-16,  发布年份 2015

【 摘 要 】

Background

Multi-drug resistance (MDR) in Gram-negative organisms is an alarming problem in the world. MDR and extensively-drug resistance (XDR) is in increasing trend due to the production of different types of beta (β)-lactamases. Thus the aim of this study was to document the incidence of MDR and XDR in clinical isolates of Escherichia coli and also to find out the enzymatic mechanisms of β-lactam antibiotics resistance.

Methods

Two hundred clinical isolates of Escherichia coli (E. coli) identified by standard laboratory methods were studied. Antibiotic susceptibility profile was performed for all the isolates and the suspected isolates were phenotypically tested for the production of extended spectrum β-lactamase (ESBL), metallo β-lactamase (MBL) and AmpC β-lactamase (AmpC) by recommended methods.

Results

Around three-fourth (78%) of the total isolates were multi-drug resistant. ESBL, MBL and AmpC production was found in 24%, 15% and 9% of isolates respectively. Amikacin, chloramphenicol and colistin were found to be the most effective antibiotics.

Conclusions

High percentage of MDR was observed. β-lactamase mediated resistance was also high. Thus, regular surveillance of drug resistance due to β-lactamases production and infection control policy are of utmost importance to minimize the spread of resistant strains.

【 授权许可】

   
2015 Ansari et al.; licensee BioMed Central.

【 参考文献 】

• [1]Singhal S, Mathur T, Khan S, Upadhyay DJ, Chugh S, Gaind R et al.. Evaluation of methods for AmpC beta-lactamase in gram negative clinical isolates from tertiary care hospitals. Indian J Med Microbiol. 2005; 23:120-4.
• [2]Thomson KS. Controversies about Extended-Spectrum and AmpC Beta-Lactamases. Emerg Infect Dis. 2001; 7:333-6.
• [3]Bradford PA. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev. 2001; 14:933-51.
• [4]Goussard S, Courvalin P. Updated sequence information for TEM beta-lactamase genes. Antimicrob Agents Chemother. 1999; 43:367-70.
• [5]Heritage J, M'Zali FH, Gascoyne-Binzi D, Hawkey PM. Evolution and spread of SHV extended-spectrum betalactamases in gram-negative bacteria. J Antimicrob Chemother. 1999; 44:309-18.
• [6]Jacoby GA, Medeiros AA. More extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 1991; 35:1697-04.
• [7]Marchandin H, Carriere C, Sirot D, Pierre HJ, Darbas H. TEM-24 produced by four different species of Enterobacteriaceae, including Providencia rettgeri, in a single patient. Antimicrob Agents Chemother. 1999; 43:2069-73.
• [8]Mugnier P, Dubrous P, Casin I, Arlet G, Collatz EA. TEM derived extended-spectrum beta-lactamase in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1996; 40:2488-93.
• [9]Palzkill T, Thomson KS, Sanders CC, Moland ES, Huang W, Milligan TW. New variant of TEM-10 beta-lactamase gene produced by a clinical isolate of Proteus mirabilis. Antimicrob Agents Chemother. 1995; 39:1199-200.
• [10]Philippon A, Labia R, Jacoby GA. Extended-spectrum beta- lactamases. Antimicrob Agents Chemother. 1989; 33:1131-6.
• [11]Cantón R, Coque TM. The CTX-M beta-lactamase pandemic. Curr Opin Microbiol. 2006; 9:466-75.
• [12]Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008; 8:159-66.
• [13]Ramphal R, Ambrose PG. Extended-spectrum beta-lactamases and clinical outcomes: current data. Clin Infect Dis. 2006; 42:164-72.
• [14]Tumbarello M, Spanu T, Sanguinetti M, Citton R, Montuori E, Leone F et al.. Bloodstream infections caused by Extended-spectrum β-lactamase producing Klebsiella pneumoniae: Risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother. 2006; 50:498-04.
• [15]Ambler RP. The structure of beta-lactamases. Philos Trans R Soc London Bio Sci. 1980; 289:321-31.
• [16]Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for b-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother. 1995; 39:1211-33.
• [17]Philippon A, Arlet G, Jacoby GA. Plasmid-determined AmpC type-lactamases. Antimicrob Agents Chemother. 2002; 46:1-11.
• [18]Odeh R, Kelkar S, Hujer AM, Bonomo RA, Schreckenberger PC, Quinn JP. Broad resistance due to plasmid-mediated AmpC betalactamases in clinical isolates of Escherichia coli. Clin Infect Dis. 2002; 35:140-5.
• [19]Wong-Beringer A, Hindler J, Loeloff M, Queenan AM, Lee N, Pegues DA et al.. Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime. Clin Infect Dis. 2002; 34:135-46.
• [20]Conceição T, Brízio A, Duarte A, Barros R. First isolation of bla (VIM-2) in Klebsiella oxytoca clinical isolates from Portugal. Antimicrob Agents Chemother. 2005; 49(1):476.
• [21]Narayanaswamy A, Mallika M. Prevalence and Susceptibility of extended spectrum beta-lactamases in urinary isolates of Escherichia coli in a Tertiary Care Hospital, Chennai-South India. Int J Med Update. 2011; 6(1):39-3.
• [22]Isenberg HD. Clinical Microbiology Procedures Handbook. 2nd ed. ASM press, Washington DC; 2004.
• [23]Clinical and Laboratory Standard Institute (CLSI). Performance standards for antimicrobial susceptibility testing. USA: CLSI: M100-S16. Wayne, PA; 2006.
• [24]Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG et al.. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012; 18:268-81.
• [25]National Committee for Clinical Laboratory Standards (NCCLS). Performance Standards for Antimicrobial Susceptibility Testing; Eighth Informational Supplement. NCCLS document M100-S8. NCCLS, Wayne, PA; 1998.
• [26]Carter MW, Oakton KJ, Warner M, Livermore DM. Detection of extended spectrum betalactamases in Klebsiella with the Oxoid combination disk method. J Clin Microbiol. 2000; 38:4228-32.
• [27]Yong D, Lee K, Yum JH, Shin HB, Rossolini GM, Chong Y. Imipenem-EDTA disc method for differentiation of metallo-ß-lactamase-producing clinical isolates of Pseudomonas spp. and Acinetobacter spp. J Clin Microbiol. 2002; 40(10):3798-01.
• [28]Rand KH, Turner B, Seifert H, Hansen C, Johnson JA, Zimmer A. Clinical laboratory detection of AmpC bet-lactamase. Does it affect patient outcome? Am J Clin Pathol. 2011; 135:572-6.
• [29]Khanal S, Joshi DR, Bhatta DR, Devkota U, Pokhrel BM. Production of multidrug resistant bacterial pathogens from tracheal aspirates of intensive care unit patients at National Institute of Neurological and Allied Sciences, Nepal. ISRN Microbiol. 2013; 2:847569.
• [30]Khadgi S, Timilsina U, Shrestha B. Plasmid profiling of multidrug resistant Escherichia coli strains isolated from urinary tract infection patients. Int J Appl Sci Biotechnol. 2013; 1(1):1-4.
• [31]Baral P, Neupane S, Marasini BP, Ghimire KR, Lekhak B, Shrestha B. High prevalence of multidrug resistance in bacterial uropathogens from Kathmandu, Nepal. BMC Res Notes. 2012; 5:38. BioMed Central Full Text
• [32]Sharma AR, Bhatta DR, Shrestha J, Banjara MR. Antimicrobial susceptibility pattern of Escherichia coli isolated from uninary tract infected patients attending Bir hospital, Nepal. J Sci Technol. 2013; 14(1):177-84.
• [33]Ibrahim ME, Bilal NE, Hamid ME. Increased multi-drug resistant Escherichia coli from hospitals in Khartoum state, Sudan. Afr Health Sci. 2012; 12(3):368-75.
• [34]Boyd LB, Atmar R, Randall GL, Hamill RJ, Steffen D, Zechiedrich L. Increased fluoroquinolone resistance with time in Escherichia coli from >17,000 patients at a large county hospital as function of culture site, age, sex, and location. BMC Infect Dis. 2008; 8:4. BioMed Central Full Text
• [35]Namboodiri SS, Opintan JA, Lijek RS, Newman MJ, Okeke IN. Quinolone resistance in Escherichia coli from Accra, Ghana. BMC Microbiol. 2011; 11:44. BioMed Central Full Text
• [36]Drago L, Nicola L, Mattina R, Vecchi ED. In vitro lselection of resistance in Escherichia coli and Klebsiella spp. at in vivo fluoroquinolone concentrations. BMC Microbiol. 2010; 10:119. BioMed Central Full Text
• [37]Chenia HY, Pillay B, Pillay D. Analysis of the mechanisms of fluoroquinolone resistance in urinary tract pathogens. J Antimicrob Chemother. 2006; 58:1274-8.
• [38]Arpin C, Dubois V, Coulange L, André C, Fischer I, Noury P et al.. Extended spectrum bata-lactamase producing Enterobacteriaceae in community and private health care centers. Antimicrob Agents Chemother. 2003; 47:3506-14.
• [39]Rodríguez-Baño J, Navarro MD, Romero L, Martínez-Martínez L, Muniain MA, Perea EJ et al.. Epidemiology and clinical of infectious caused by extended-spectrum bata-lactamase producing Escherichia coli in nonhospitalized patients. J Clin Microbiol. 2004; 42:1089-94.
• [40]Brigante G, Luzzaro F, Perilli M, Lombardi G, Colì A, Rossolini GM et al.. Evolution of CTX-M-type beta-lactamases in isolates of Escherichia coli infecting hospital and community patients. Int J Antimicrob Agents. 2005; 25:157-62.
• [41]Chander A, Shrestha CD. Prevalence of extended spectrum beta lactamase producing Escherichia coli and Klebsiella pneumoniae urinary isolates in a tertiary care hospital in Kathmandu, Nepal. BMC Res Notes. 2013; 6:487. BioMed Central Full Text
• [42]Wadekar MD, Anuradha K, Venkatesha D. Phenotypic detection of ESBL and MBL in clinical isolates of Enterobacteriaceae. Int J Current Res Acad Rev. 2013; 1(3):89-5.
• [43]Altun S, Tufan ZK, Yağcı S, Önde U, Bulut C, Kiniki S et al.. Extended spectrum beta-lactamases, AmpC and metallo beta-lactamases in emerging multi-drug resistant Gram-negative bacteria in intensive care unit. Sci Rep. 2013; 2(4):707.
• [44]Kaur J, Chopra S, Sheevani Mahajan G. Modified double disc synergy test to detect ESBL production in urinary isolates of Escherichia coli and Klebsiella pneumonia. J Cli Diag Res. 2013; 7(2):229-33.
• [45]Bourjilat F, Bouchrif B, Dersi N, Claude JD, Amarouch H, Timinouni M. Emergence of extended-spectrum beta-lactamase-producing Escherichia coli in community-acquired urinary infections in Casablanca, Morocco. J Infect Dev Ctries. 2011; 5(12):850-5.
• [46]Aly MEA, Essam TM, Amin MA. Antibiotic resistance profile of Escherichiaa coli strains isolated from clinical specimens and food samples in Egypt. Int J Microbiol Res. 2012; 3(3):176-82.